OnabotulinumToxinA Reduces Pharmacological Burden in Chronic Migraine Patients: A Two-Center Prospective Cohort Study
Treatment with BTx was associated with a reduction in drug burden at 12 months and a CM to EM conversion rate of almost 60% at 12 months, also contributing to a reduction in the economic burden of the disease.
Authors
- Luigi d’Onofrio (ORCID: https://orcid.org/0009-0006-3387-4013)
- Marilena Marcosano (ORCID: https://orcid.org/0009-0003-5191-7628)
- Alessia Marcassoli (ORCID: https://orcid.org/0000-0002-5003-1409)
- Fabrizio Vernieri (ORCID: https://orcid.org/0000-0002-9594-9336)
- Danilo Antonio Montisano (ORCID: https://orcid.org/0000-0003-4834-2045)
- Alessandra Parisi
- Luisa Fofi
- Alberto Raggi
- Licia Grazzi
- Claudia Altamura
Institutions
- Università Campus Bio-Medico (IT)
- Campus Bio Medico University Hospital (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
Publication Details
- Journal
- Toxins
- Published
- 2026-03-14
- DOI
- https://doi.org/10.3390/toxins18030143
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00